In our previous report we provided estimates of this metric???s efficiency at the discrimination of cognitively normal, control subjects (CTRL) from probable AD patients, as well as the prediction of conversion in mild cognitive impairment (MCI) subjects to probable AD. Thorough technique verification, validation, and evaluation are necessary, however, in order for imaging biomarkers such as the D